Location of Repository

Luteinizing hormone-releasing hormone antagonists in patients with prostate cancer. A standard approach and the results of innovative studies

By K. M. Nyushko, B. Ya. Alekseev, A. S. Kalpinsky and A. D. Kaprin

Abstract

<p>Prostate cancer (PC) is one of the most burning problems of modern urologic oncology. Hormonal therapy (HT) using medical castration<br />remains a basic therapy for metastatic PC. HT with a novel class of luteinizing hormone-releasing hormone (LHRH) receptor antagonists is<br />a promising and effective castration treatment option that has a number of significant advantages over LHRH analogues. The paper reviews the results of trials comparing the efficiency and adverse reactions of HT using LHRH antagonists and analogues and gives those of a Russian multicenter study covering the countrywide experience with degarelix.</p

Topics: рак предстательной железы, аналоги и антагонисты лютеинизирующего гормона рилизинг-гормона, дегареликс, кастрационная рефрактерность, сердечно-сосудистая патология, кардиоваскулярный риск, Medicine, R
Publisher: ABV-press
Year: 2014
OAI identifier: oai:doaj.org/article:92304d060ab34fd9934f04800a352c09
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/1996-1812 (external link)
  • https://doaj.org/toc/1726-9776 (external link)
  • http://oncourology.abvpress.ru... (external link)
  • https://doaj.org/article/92304... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.